stars 1 stars 2 stars 3

Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis. The company’s singular mission is to improve and prolong the lives of patients suffering from this disease. Launched in 2016 after years of research supported by Stanford’s SPARK program, Eidos is led by a team of veteran biotechnology executives. Together with patients and physicians, the company aims to bring a safe, effective treatment to market as quickly as possible.

Eidos Therapeutics Questions

The Eidos Therapeutics annual revenue was $12.7 million in 2026.

Uma Sinha is the Chief Scientific Officer of Eidos Therapeutics.

26 people are employed at Eidos Therapeutics.

Eidos Therapeutics is based in San Francisco, California.

The NAICS codes for Eidos Therapeutics are [54171, 541712, 541711, 541, 54, 5417].

The SIC codes for Eidos Therapeutics are [87, 873].

Top Eidos Therapeutics Employees

View Similar People
Learn More
How It Works
get free account
Get a Free Account
Sign up for a free account. No credit card required. Up to 5 free lookups.
search page
Search the #1 Contact Database
Get contact details of over 700M profiles across 60M companies – all with industry-leading accuracy. Sales and Recruiter users, try out our Email Finder Extension.
get contact page
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.
G2 Leader Winter 2026 G2 Leader Mid Market Winter 2026 G2 Leader Small Business Winter 2026 G2 Most Implementable Winter 2026 G2 Best Est ROI Mid Market Winter 2026 G2 Leader Momentum Winter 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2025
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users